Show simple item record

dc.contributor.authorLynch, Julie A.
dc.contributor.authorKhoury, Muin J.
dc.contributor.authorBorzecki, Ann M.
dc.contributor.authorCromwell, Jerry
dc.contributor.authorHayman, Laura L.
dc.contributor.authorPonte, Pat Reid
dc.contributor.authorMiller, Glenn A.
dc.contributor.authorLathan, Christopher S.
dc.date2022-08-11T08:08:29.000
dc.date.accessioned2022-08-23T15:57:05Z
dc.date.available2022-08-23T15:57:05Z
dc.date.issued2013-08-01
dc.date.submitted2014-03-31
dc.identifier.citation<p>Genet Med. 2013 Aug;15(8):630-8. doi: 10.1038/gim.2013.5. Epub 2013 Feb 28. <a href="http://dx.doi.org/10.1038/gim.2013.5">Link to article on publisher's site</a></p>
dc.identifier.issn1098-3600 (Linking)
dc.identifier.doi10.1038/gim.2013.5
dc.identifier.pmid23448725
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30114
dc.description.abstractPURPOSE: We examined hospital use of the epidermal growth factor receptor assay in patients with lung cancer in the United States. Our goal was to inform the development of a model to predict phase 3 translation of guideline-directed molecular diagnostic tests. METHODS: This was a retrospective observational study. Using logistic regression, we analyzed the association between hospitals' institutional and regional characteristics and the likelihood that an epidermal growth factor receptor assay would be ordered. RESULTS: Significant institutional predictors included affiliation with an academic medical center (odds ratio, 1.48; 95% confidence interval, 1.20-1.83), participation in a National Cancer Institute clinical research cooperative group (odds ratio, 2.06, 1.66-2.55), and -availability of positron emission tomography scan (odds ratio, 1.44, 1.07-1.94) and cardiothoracic surgery (odds ratio, 1.90, 1.52-2.37) services. Significant regional predictors included metropolitan county (odds ratio, 2.08, 1.48-2.91), population with above-average education (odds ratio, 1.46, 1.09-1.96), and population with above-average income (odds ratio, 1.46, 1.04-2.05). Distance from a National Cancer Institute cancer center was a negative predictor (odds ratio, 0.996, 0.995-0.998), with a 34% decrease in likelihood for every 100 miles. CONCLUSION: In 2010, only 12% of US acute-care hospitals ordered the epidermal growth factor receptor assay, suggesting that most patients with lung cancer did not have access to this test. This case study illustrated the need for: (i) increased dissemination and implementation research, and (ii) interventions to improve adoption of guideline-directed molecular diagnostic tests by community hospitals.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23448725&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800006/
dc.subjectUMCCTS funding
dc.subjectequity
dc.subjectaccess
dc.subjectlung
dc.subjectcancer
dc.subjectgenomics
dc.subjectCommunity Health and Preventive Medicine
dc.subjectDiagnosis
dc.subjectGenetics and Genomics
dc.subjectHealth Services Administration
dc.subjectMedical Genetics
dc.subjectMolecular Genetics
dc.subjectNeoplasms
dc.subjectRespiratory Tract Diseases
dc.subjectTranslational Medical Research
dc.titleUtilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research
dc.typeJournal Article
dc.source.journaltitleGenetics in medicine : official journal of the American College of Medical Genetics
dc.source.volume15
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/352
dc.identifier.contextkey5413925
html.description.abstract<p>PURPOSE: We examined hospital use of the epidermal growth factor receptor assay in patients with lung cancer in the United States. Our goal was to inform the development of a model to predict phase 3 translation of guideline-directed molecular diagnostic tests.</p> <p>METHODS: This was a retrospective observational study. Using logistic regression, we analyzed the association between hospitals' institutional and regional characteristics and the likelihood that an epidermal growth factor receptor assay would be ordered.</p> <p>RESULTS: Significant institutional predictors included affiliation with an academic medical center (odds ratio, 1.48; 95% confidence interval, 1.20-1.83), participation in a National Cancer Institute clinical research cooperative group (odds ratio, 2.06, 1.66-2.55), and -availability of positron emission tomography scan (odds ratio, 1.44, 1.07-1.94) and cardiothoracic surgery (odds ratio, 1.90, 1.52-2.37) services. Significant regional predictors included metropolitan county (odds ratio, 2.08, 1.48-2.91), population with above-average education (odds ratio, 1.46, 1.09-1.96), and population with above-average income (odds ratio, 1.46, 1.04-2.05). Distance from a National Cancer Institute cancer center was a negative predictor (odds ratio, 0.996, 0.995-0.998), with a 34% decrease in likelihood for every 100 miles.</p> <p>CONCLUSION: In 2010, only 12% of US acute-care hospitals ordered the epidermal growth factor receptor assay, suggesting that most patients with lung cancer did not have access to this test. This case study illustrated the need for: (i) increased dissemination and implementation research, and (ii) interventions to improve adoption of guideline-directed molecular diagnostic tests by community hospitals.</p>
dc.identifier.submissionpathfaculty_pubs/352
dc.contributor.departmentUMass Center for Clinical and Translational Science
dc.source.pages630-8


This item appears in the following Collection(s)

Show simple item record